A review of the adverse effects of peripheral alpha-I antagonists in hypertension therapy

Current Controlled Trials in Cardiovascular Medicine

Volumn 3, Issue , 2002, Pages

  Bryson, Chris L ^a   Psaty, Bruce M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; NORADRENALIN; PRAZOSIN; TERAZOSIN;

ANTIHYPERTENSIVE THERAPY; BODY WEIGHT DISORDER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FLUID RETENTION; HEART FAILURE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; NORADRENALIN BLOOD LEVEL; OUTCOMES RESEARCH; REVIEW; SAMPLE SIZE; WEIGHT GAIN;

EID: 26044434458     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. The ALLHAT Officer: and Coordinators for the ALLHAT Collaborative Research Project: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975
2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Archives of Internal Medicine 1997, 157:2413-2446
3. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New England Journal of Medicine 1996, 335:533-539
4. Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. Urologic Clinics of North America 1990, 17:495-507
5. Nelson CR, Knapp DA: Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension (Online) 2000, 36:600-603
6. Mehta SS, Wilcox CS, Schulman KA: Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). American Journal of Hypertension 1999, 12:333-340
7. Bauer JH, Jones LB, Gaddy P: Effects of prazosin therapy on BP, renal funccion, and body fluid composition. Archives of Internal Medicine 1984, 144:1196-1200
8. Deger G: Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986, 80:62-67
9. Letcher RL, Chien S, Laragh JH: Changes in blood viscosity accompanying the response to prazosin in patients with essential hypertension. Journal of Cardiovascular Pharmacology 1979, 1:S8-20
10. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997, 95:2007-2014
11. Materson BJ: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. New England Journal of Medicine 1993, 328:914-921
12. Ruoff G: Effect of withdrawal of terazosin therapy in patients with hypertension. American Journal of Medicine 1986, 80:35-41
13. Lund-Johansen P, Omvik P, Haugland H: Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. British Journal of Clinical Pharmacology 1986, 21 (Suppl 1):45S-54S
14. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993, 270:713-724
15. Rona G: Catecholamine cardiotoxicity. Journal of Molecular & Cellular Cardiology 1985, 17:291-306
16. Communal C, Singh K, Pimentel DR, Colucci WS: No repinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998, 98:1329-1334
17. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S: Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 1999, 100:305-311
18. Luscher TF, Barton M: Endothelins and Endothelin Receptor Antagonists Therapeutic Considerations for a Novel Class of Cardiovascular Drugs. Circulation 2000, 102:2434-2440
19. Seljeflot I, Arnesen H, Andersen P, Aspelin T, Kierulf P: Effects of doxazosin and atenolol on circulating endothelin-I and von Willebrand factor in hypertensive middle-aged men. Journal of Cardiovascular Pharmacology 1999, 34:584-588
20. Hooper PL: Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosila. Journal of Human Hypertension 2001, 15:285
21. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997, 278:212-216
22. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH: Diuretic therapy for hypertension and the risk of primary cardiac arrest. New England Journal of Medicine 1994, 330:1852-1857
23. Cupples L, D'Agostino R: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. Section 34: Bethesda: National Institutes of Health, 1987. NIH Pub. No. 87-2703; 1987
24. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K: Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. American Journal of Cardiology 1984, 54:783-786
25. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI: Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986, 73:615-621
26. Gomberg-Maitland M: Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and Heart Failure Specialist. Arch Int Med 2001, 161:342-353
27. Sperzel WD, Glassman HN, Jordan DC, Luther RR: Overall safety of terazosin as an antihypertensive agent. American Journal of Medicine 1986, 80:77-81
28. Luther RR, Glassman HN, Estep CB, Schmitz PJ, Horton JK, Jordan DC: Terazosin, a new selective alpha I-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. American Journal of Hypertension 1988, 1:237S-240S
29. Mersey JH: Long-term experience with terazosin for treatment of mild to moderate hypertension. American Journal of Medicine 1986, 80:68-72
30. Ames RP, Chrysant SG, Gonzalez F, Schnaper HW, Spann S, Velasquez MT: Effectiveness of doxazosin in systemic hypertension. American Journal of Cardiology 1989, 64:203-208
31. Carruthers G, Dessain P, Fodor G, Newman C, Palmer W, Sim D: Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. American Journal of Cardiology 1993, 71:575-581
32. Ott P, Storm TL, Krusell LR, Jensen H, Badskjaer J, Faergeman O: Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. American Journal of Cardiology 1987, 59:73G-77G
33. Torvik D, Madsbu HP: Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. British Journal of Clinical Pharmacology 1986, 21 (Suppl 1):69S-75S
34. Grimm RH, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, Lewis C, McDonald R, Schoenberger J, Stamler J: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275:1549-1556
35. Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M: Doxazosin withdrawal and ambulatory blood pressure monitoring in normotensiye subjects. Angiology 1994, 45:17-23
36. Izzo JL Jr, Licht MR, Smith RJ, Larrabee PS, Radke KJ, Kallay MC: Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. American Journal of Cardiology 1987, 60:303-308
37. Colucci WS, Williams GH, Braunwald E: Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Annals of Internal Medicine 1980, 93:452-453
38. Stein L, Henry DP, Weinberger MH: Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. American Journal of Medicine 1981, 70:825-832
39. Markham RV, Corbett JR, Gilmore A, Pettinger WA, Firth BG: Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. American Journal of Cardiology 1983, 51:1346-1352